Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: Associations with clinicopathological parameters and patients survival

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 2, 2011, Pages 251-259

  Theocharis, Stamatios ^a,b   Klijanienko, Jerzy ^a   Giaginis, Constantinos ^b   Rodriguez, Jose ^a   Jouffroy, Thomas ^a   Girod, Angelique ^a   Point, Daniel ^a   Tsourouflis, Gerasimos ^b   Satre Garau, Xavier ^a  

^a INSTITUT CURIE   (France)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clinicopathological parameters; Immunohistochemistry; Mobile tongue; PPAR ; Prognosis; Squamous cell carcinoma

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; MITOSIS INDEX; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TONGUE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLOSSECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM INVASIVENESS; PPAR GAMMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78751609332     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0882-z     Document Type: Article

References (44)

1. Barnes L, Eveson JW, Reichert P, Sidransky D (2005) World Health Organization classifications tumours, pathology and genetics of head and neck tumours. IARC Press, Lyon
2. RB Bell D Kademani L Homer EJ Dierks BE Potter 2007 Tongue cancer: is there a difference in survival compared with other subsites in the oral cavity J Oral Maxillofac Surg 65 2 229 236 10.1016/j.joms.2005.11.094 10.1016/j.joms.2005.11.094 17236926 (Pubitemid 46127604)
3. C Blanquicett J Roman CM Hart 2008 Thiazolidinediones as anti-cancer agents Cancer Ther 6 A 25 34 1:CAS:528:DC%2BD1cXht1KgsbfL 19079765
4. M Brandwein-Gensler MS Teixeira CM Lewis B Lee JJ Rolnitzky JJ Hille, et al. 2005 Oral squamous cell carcinoma: histological risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival Am J Surg Pathol 29 2 167 178 10.1097/01.pas.0000149687.90710.21 15644773 (Pubitemid 40170634)
5. H Brenner 2002 Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis Lancet 360 9340 1131 1135 10.1016/S0140-6736(02)11199-8 10.1016/S0140-6736(02)11199-8 12387961 (Pubitemid 35246487)
6. E Burgermeister R Selker 2007 MAPK kinases as nucleo-cytoplasmic shuttles of PPARγ Cell Cycle 6 13 1539 2548 1:CAS:528:DC%2BD2sXhtFWlsrzI 10.4161/cc.6.13.4453 17611413
7. KA Burns JP Vanden Heuvel 2007 Modulation of PPAR activity via phosphorylation Biochim Biophys Acta 1771 8 952 960 10.1016/j.bbalip.2007.04.018 1:CAS:528:DC%2BD2sXovFensrY%3D 17560826 (Pubitemid 47198547)
8. MT Canto SS Devesa 2002 Oral cavity and pharynx cancer incidence in the United States, 1975-1988 Oral Oncol 38 6 610 617 10.1016/S1368-8375(01)00109-9 10.1016/S1368-8375(01)00109-9 12167440 (Pubitemid 34880123)
9. L Döbrossy 2005 Epidemiology of head and neck cancer: magnitude of the problem Cancer Metastasis Rev 24 1 9 17 10.1007/s10555-005-5044-4 10.1007/s10555-005-5044-4 15785869 (Pubitemid 40584773)
10. C Giaginis A Tsantili-Kakoulidou S Theocharis 2007 Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism Fundam Clin Pharmacol 21 3 231 244 1:CAS:528:DC%2BD2sXmvValsrc%3D 10.1111/j.1472-8206.2007.00486.x 17521292 (Pubitemid 46800478)
11. C Giaginis G Tsourouflis S Theocharis 2008 Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury Curr Mol Med 8 6 562 579 1:CAS:528:DC%2BD1cXhtVGqu7rK 10.2174/156652408785748022 18781963
12. C Giaginis A Tsantili-Kakoulidou S Theocharis 2008 Peroxisome proliferator-activated receptor-gamma ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer PPAR Res 2008 431763 18464916
13. C Giaginis E Katsamangou G Tsourouflis D Zizi-Serbetzoglou G Kouraklis S Theocharis 2009 Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival Med Sci Monit 15 5 BR148 BR156 1:CAS:528:DC%2BD1MXnslWhtbc%3D 19396032
14. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics CA Cancer J Clin 57 1 43 66 10.3322/canjclin.57.1.43 10.3322/canjclin.57.1.43 17237035
15. Y Jiang L Zou C Zhang S He C Cheng J Xu, et al. 2009 PPARgamma and Wnt/beta-catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations J Cancer Res Clin Oncol 135 11 1551 1559 10.1007/s00432-009-0602-8 1:CAS:528:DC%2BD1MXhtFCjtb%2FF 10.1007/s00432-009-0602-8 19495794
16. S Kantola M Parikka K Jokinen K Hyrynkangs Y Soini O-P Alho T Salo 2000 Prognostic factors in tongue cancer-relative importance of demographic, clinical and histopathological factors Br J Cancer 83 5 614 619 10.1054/bjoc.2000.1323 1:STN:280:DC%2BD3cvjt1Omtw%3D%3D 10.1054/bjoc.2000.1323 10944601
17. HJ Kim JY Hwang HJ Kim WS Choi HJ Kim JH Lee, et al. 2007 Expression of a peroxisome proliferator-activated receptor γ1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress Clin Cancer Res 13 9 2577 2583 10.1158/1078-0432.CCR-06-2062 1:CAS:528:DC%2BD2sXkslOhtLg%3D 10.1158/1078-0432.CCR-06-2062 17473186 (Pubitemid 46788022)
18. J Klijanienko AK el-Naggar F de Braud JL Rodriguez-Peralto R Rodriguez M Itzhaki, et al. 1995 Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas Cancer 75 7 1649 1656 1:STN:280:DyaK28visVCjsg%3D%3D 10.1002/1097-0142(19950401)75:7<1649::AID-CNCR2820750715>3.0.CO;2-E 8826923
19. PC Konturek A Nikiforuk J Kania M Raithel EG Hahn S Mühldorfer 2004 Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors Dig Dis Sci 49 7-8 1075 1083 10.1023/B:DDAS.0000037790.11724.70 1:CAS:528: DC%2BD2cXms1CgtLw%3D 10.1023/B:DDAS.0000037790.11724.70 15387324 (Pubitemid 39178068)
20. G Kristiansen J Jacob AC Buckendahl R Grützmann I Alldinger B Sipos, et al. 2006 Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times Clin Cancer Res 12 21 6444 6451 10.1158/1078-0432.CCR-06-0834 1:CAS:528:DC%2BD28XhtFKitbzE 10.1158/1078-0432.CCR-06-0834 17085658 (Pubitemid 44799717)
21. L Michalik W Wahli 2008 PPARs mediate lipid signaling in inflammation and cancer PPAR Res 2008 134059 10.1155/2008/134059 19125181
22. P Mukunyadzi L Ai D Portilla EL Barnes CY Fan 2003 Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases Mod Pathol 16 12 1218 1223 10.1097/01.MP.0000096042.70559.7E 14681322 (Pubitemid 38018603)
23. E Mylona I Giannopoulou K Diamantopoulou P Bakarakos A Nomikos A Zervas L Nakopoulou 2009 Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome Eur J Surg Oncol 35 2 197 201 10.1016/j.ejso.2008.04.003 1:STN:280:DC%2BD1M%2Fns1Kksw%3D%3D 18513919
24. S Ogino K Shima Y Baba K Nosho N Irahara S Kure, et al. 2009 Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis Gastroenterology 136 4 1242 1250 10.1053/j.gastro.2008.12.048 1:CAS:528:DC%2BD1MXkslWgsbs%3D 10.1053/j.gastro. 2008.12.048 19186181
25. F Ondrey 2009 Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention Clin Cancer Res 15 1 2 8 10.1158/1078-0432.CCR-08-0326 1:CAS:528:DC%2BD1MXhs1ektg%3D%3D 10.1158/1078-0432.CCR-08-0326 19118026
26. I Papadaki E Mylona I Giannopoulou S Markaki A Keramopoulos L Nakopoulou 2005 PPARγ expression in breast cancer: clinical value and correlation with ERβ Histopathology 46 1 37 42 1:STN:280:DC%2BD2M%2FnsFSitA%3D%3D 10.1111/j.1365-2559.2005.02056.x 15656884 (Pubitemid 40193696)
27. RS Patel JR Clark R Dirven R Wyten K Gao CJ O'Brien 2009 Prognostic factors in the surgical treatment of patients with oral carcinoma ANZ J Surg 79 1-2 19 22 10.1111/j.1445-2197.2008.04791.x 10.1111/j.1445-2197.2008.04791.x 19183373
28. A Po Wing Yen KY Lam WI Wei LK Lam CM Ho TL Chow WF Yuen 2000 A comparison of prognostic significance of tumor diameter, length, width, thickness area, volume and clinicopathological features of oral tongue carcinoma Am J Surg 180 2 139 143 10.1016/S0002-9610(00)00433-5
29. A Po Wing Yen KY Lam LK Lam CM Ho A Wong TL Chow, et al. 2002 Prognostic factors clinically stage I and II oral tongue carcinoma: a comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score and pathologic features Head Neck 24 6 513 520 10.1002/hed.10094 (Pubitemid 34568551)
30. M Sahin BL Allard M Yates JG Powell XL Wang ID Hay, et al. 2005 PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value J Clin Endocrinol Metab 90 1 463 468 10.1210/jc.2004-1203 1:CAS:528:DC%2BD2MXlvFCisA%3D%3D 10.1210/jc.2004-1203 15483076 (Pubitemid 40116695)
31. D Sano JN Myers 2007 Metastasis of squamous cell carcinoma of the oral tongue Cancer Metastasis Rev 26 3-4 645 662 10.1007/s10555-007-9082-y 1:CAS:528:DC%2BD2sXht1yktLbI 10.1007/s10555-007-9082-y 17768600 (Pubitemid 350115112)
32. P Sarraf E Mueller WM Smith HM Wright JB Kum LA Aaltonen, et al. 1999 Loss-of-function mutations in PPARγ associated with human colon cancer Mol Cell 3 6 799 804 10.1016/S1097-2765(01)80012-5 1:CAS:528:DyaK1MXktlOktbY%3D 10.1016/S1097-2765(01)80012-5 10394368 (Pubitemid 29323058)
33. CH Shiboski BL Schmidt RC Jordan 2005 Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years Cancer 103 9 1843 1849 10.1002/cncr.20998 15772957 (Pubitemid 40563256)
34. S Shintani H Matsuura Y Hasegawa B Nakayama Y Fujimoto 1997 The relationship of shape of tumor invasion to depth of invasion and cervical lymph node metastasis in squamous cell carcinoma of the tongue Oncology 54 6 463 467 1:STN:280:DyaK1c%2Fls1yhtg%3D%3D 10.1159/000227604 9394842
35. H Takahashi K Fujita T Fujisawa K Yonemitsu A Tomimoto I Ikeda, et al. 2006 Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties Cancer Sci 97 9 854 860 1:CAS:528:DC%2BD28XpsFelsLw%3D 10.1111/j.1349-7006.2006. 00250.x 16805824 (Pubitemid 44151265)
36. T Takashima Y Fujiwara K Higuchi T Arakawa Y Yano T Hasuma S Otani 2001 PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity Int J Oncol 19 3 465 471 1:CAS:528:DC%2BD3MXms1SjtL4%3D 11494023
37. T Takashima Y Fujiwara M Hamaguchi E Sasaki K Tominaga T Watanabe, et al. 2005 Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma Oncol Rep 13 4 601 606 1:CAS:528:DC%2BD2MXjtFans7o%3D 15756430
38. Y Terashita H Sasaki N Haruki T Nishiwaki H Ishiguro Y Shibata, et al. 2002 Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer Jpn J Clin Oncol 32 7 238 243 10.1093/jjco/hyf056 12324573 (Pubitemid 43102806)
39. S Theocharis H Kanelli E Politi A Margeli C Karkandaris T Philippides A Koutselinis 2002 Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade Lung Cancer 36 3 249 255 10.1016/S0169-5002(02)00013-2 12009233 (Pubitemid 34497122)
40. S Theocharis C Giaginis A Parasi A Margeli J Kakisis E Agapitos G Kouraklis 2007 Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival Dig Dis Sci 52 9 2305 2311 1:CAS:528:DC%2BD2sXoslGis70%3D 10.1007/s10620-007-9794-4 17393321 (Pubitemid 47246534)
41. J Tímár O Csuka E Remenár G Répássy M Kásler 2005 Progression of head and neck squamous cell cancer Cancer Metastasis Rev 24 1 107 127 10.1007/s10555-005-5051-5 10.1007/s10555-005-5051-5 15785876 (Pubitemid 40576067)
42. D Wangsa M Ryott E Avall-Lundquist F Petersson G Elmberg J Luo, et al. 2008 Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma Br J Cancer 99 7 1121 1128 10.1038/sj.bjc.6604633 1:CAS:528: DC%2BD1cXhtFyqt7vL 10.1038/sj.bjc.6604633 18766188
43. K Yoshida Y Hirose T Tanaka Y Yamada T Kuno H Kohno, et al. 2003 Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide Cancer Sci 94 4 365 371 1:CAS:528:DC%2BD3sXkslCns70%3D 10.1111/j.1349-7006.2003.tb01448.x 12824906 (Pubitemid 36626370)
44. GY Zhang N Ahmed C Riley K Oliva G Barker MA Quinn GE Rice 2005 Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma Br J Cancer 92 1 113 119 10.1038/sj.bjc.6602244 1:CAS:528:DC%2BD2MXhtV2qu7c%3D 10.1038/sj.bjc.6602244 15583697 (Pubitemid 40188443)